アブストラクト
Japanese
| Title | ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴 |
|---|---|
| Subtitle | ノート |
| Authors | 清木静乃1, 山下修司1,2, 鏑木美帆3, 玉木啓文2,4, 野口義紘2,5, 長内理大2,4, 伊野陽子2,4, 井口和弘2,4, 寺町ひとみ2,3,5, 林秀樹1,3 |
| Authors (kana) | |
| Organization | 1岐阜薬科大学地域医療実践薬学研究室, 2岐阜薬科大学附属薬局, 3岐阜薬科大学地域医療薬学寄附講座, 4岐阜薬科大学薬局薬学研究室, 5岐阜薬科大学病院薬学研究室 |
| Journal | 医療薬学 |
| Volume | 49 |
| Number | 2 |
| Page | 66-73 |
| Year/Month | 2023 / 2 |
| Article | 報告 |
| Publisher | 日本医療薬学会 |
| Abstract | 「緒言」ステロイド性骨粗鬆症(glucocorticoid-induced osteoporosis: GIO)は, 続発性骨粗鬆症の代表的な病態の1つであり, 長期的な糖質コルチコイド(glucocorticoid: GC)治療によって引き起こされる医原性合併症として知られている. GCは主に抗炎症作用や免疫抑制作用を期待して投与され, 自己免疫疾患, 呼吸器疾患および血液疾患など多領域の疾患に対して適応を有するため, 幅広い診療科から処方される薬剤である. これまでの報告によれば, GC は総人口の約0.79-1.2%に投与されており, 経口GCが投与された患者の骨折リスクは投与開始から3-6カ月以内に上昇し, また骨折リスク増加がGCの1日投与量と強く関連する. 骨折リスク上昇に伴い患者が骨折に至った場合, 患者の日常生活動作(activities of daily living: ADL)や生活の質(quality of life: QOL)の低下が問題となる. |
| Practice | 薬学 |
| Keywords | glucocorticoid-induced osteoporosis prevention, fracture risk factor, glucocorticoid dosage, guidelines, community pharmacists |
English
| Title | Actual Situation and Characteristics of Pharmacotherapy for Glucocorticoid-induced Osteoporosis Prevention |
|---|---|
| Subtitle | Notes |
| Authors | Shizuno Seiki1, Shuji Yamashita1,2, Miho Kaburaki3, Hirofumi Tamaki2,4, Yoshihiro Noguchi2,5, Arihiro Osanai2,4, Yoko Ino2,4, Kazuhiro Iguchi2,4, Hitomi Teramachi2,3,5, Hideki Hayashi1,3 |
| Authors (kana) | |
| Organization | 1Laboratory of Pharmacy Practice and Community Healthcare, Gifu Pharmaceutical University, 2Gifu Pharmaceutical University Pharmacy, 3Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University, 4Laboratory of Community Pharmacy, Gifu Pharmaceutical University, 5Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University |
| Journal | Japanese Journal of Pharmaceutical Health Care and Sciences |
| Volume | 49 |
| Number | 2 |
| Page | 66-73 |
| Year/Month | 2023 / 2 |
| Article | Report |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Abstract | Glucocorticoid-induced osteoporosis (GIO) is a serious side effect of long-term glucocorticoid (GC) administration. However, sufficient high compliance rate data for the guidelines on the management and treatment of GIO in Japan is unavailable. Additionally, GC is prescribed at many medical departments involved in outpatient care. Community pharmacists might intervene to support more appropriate pharmacotherapy to avoid GIO. This study examines the actual state and characteristics of pharmacotherapy for GIO prevention. We investigated 136 patients from the Gifu Pharmaceutical University pharmacy that received GC treatment continuously for over three months. We obtained the age, GC dosage, and combined medications data retrospectively from the electronic drug system and assessed the fracture risk factor using a scoring system. One hundred and two patients were recommended for prophylactic pharmacotherapy based on the guidelines on the management and treatment of GIO. Nineteen patients (18.6%) did not receive this therapy. Thus, community pharmacists should consider proposing prescriptions using the guidelines and help support GIO prevention. |
| Practice | Pharmaceutical sciences |
| Keywords | glucocorticoid-induced osteoporosis prevention, fracture risk factor, glucocorticoid dosage, guidelines, community pharmacists |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Chotiyarnwong P, McCloskey EV, Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment, Nat Rev Endocrinol, 2020, 16, 437-447.
- 2) Overman RA, Yeh JY, Deal CL, Prevalence of oral glucocorticoid usage in the United States: a general population perspective, Arthritis Care Res (Hoboken), 2013, 65, 294-298.
- 3) Fardet L, Petersen I, Nazareth I, Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years, Rheumatology (Oxford), 2011, 50, 1982-1990.
- 4) van Staa TP, Leufkens HGM and Cooper C, The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis, Osteoporos Int, 2002, 13, 777-787.
- 5) van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology (Oxford), 2000, 39, 1383-1389.
残りの15件を表示する
- 6) van de Ree CLP, Landers MJF, Kruithof N, de Munter L, Slaets JPJ, Gosens T, de Jongh MAC, Effect of frailty on quality of life in elderly patients after hip fracture: a longitudinal study, BMJ Open, 2019, 9, e025941. doi:10.1136/bmjopen-2018-025941.
- 7) Tosteson AN, Gottlieb DJ, Radley DC, Fisher ES, Melton LJ III, Excess mortality following hip fracture: the role of underlying health status, Osteoporos Int, 2007, 18, 1463-1472.
- 8) 岸 陽子, 浦岡秀行, 高齢者大腿骨頸部骨折術後の予後調査, 整形外科と災害外, 2004, 58, 125-128.
- 9) Hsu E, Nanes M, Advances in treatment of glucocorticoid-induced osteoporosis, Curr Opin Endocrinol Diabetes Obes, 2017, 24, 411-417.
- 10) Adami G, Saag KG, Glucocorticoid-induced osteoporosis: 2019 concise clinical review, Osteoporos Int, 2019, 30, 1145-1156.
- 11) Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y, Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis, Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004), J Bone Miner Metab, 2005, 23, 105-109.
- 12) Kirigaya D, Nakayama T, Ishizaki T, Ikeda S, Satoh T, Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors, Intern Med, 2011, 50, 2793-2800.
- 13) Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y, Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update, J Bone Miner Metab, 2014, 32, 337-350.
- 14) 宇野智江, 野村賢一, 石川茂樹, 余語鎮治, 金山康秀, 全国厚生連病院を対象としたステロイド性骨粗鬆症の管理に関する調査, 日本農村医学会雑誌, 2018, 67, 144-148.
- 15) 河野哲也, 柏倉 剛, 相澤俊朗, 宮腰尚久, 島田洋一, AORA (Akita Orthopedic Group on Rheumatoid Arthritis) registry 2017 におけるステロイド性骨粗鬆症の治療現状, 東日本整形災害外科学会雑誌, 2019, 31, 171-176.
- 16) Iki M, Fujimori K, Nakatoh S, Tamaki J, Ishii S, Okimoto N, Kamiya K, Ogawa S, Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan, Bone, 2022, 160, 116396. doi:10.1016/j.bone.2022.116396.
- 17) Moriwaki K, Fukuda H, Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan, Osteoporos Int, 2019, 30, 299-310.
- 18) Chiodini I, Falchetti A, Merlotti D, Eller Vainicher C, Gennari L, Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis, Expert Rev Endocrinol Metab, 2020, 15, 283-298.
- 19) 岸本裕充, 高岡一樹, 骨吸収抑制薬関連顎骨壊死の最新情報, 日本口腔インプラント学会誌, 2017, 30, 191-199.
- 20) 実務実習テキスト作成委員会,"モデル・コアカリキュラムに沿ったわかりやすい新実務実習テキスト 2023-2024", じほう, 東京, 2022, pp308-312.
